biote
biote's revenue fell 2.5% to $192 million in fiscal 2025. Its operating margin was 18.5%, up from 16.0% a year earlier. Free cash flow was $30 million, down 22.2%. It paid out $5 million in dividends and buybacks, 17% of free cash flow. The diluted share count rose 7.0%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What biote does
biote trains doctors and other medical practitioners to run hormone therapy practices, mostly for women going through menopause and men with low testosterone. Its program, the Biote Method, includes training and certification, software that helps set each patient's dose and track inventory, marketing support for the clinic, and access to outside compounding pharmacies that make the hormone pellets the practitioners prescribe. The company compares the setup to a franchise. Patients pay the clinics directly, rather than through insurance.
It makes money in two ways: fees that partner clinics pay under long-term service agreements, charged per procedure, and sales of its own brand of dietary supplements, which practitioners recommend to their patients. It reports one business segment. Revenue was $192.2 million in 2025, against $197.2 million in 2024.
At the end of 2025 biote worked with over 9,200 certified practitioners in more than 5,300 partner clinics across the United States. Its business is concentrated in 10 core states, which brought in about 53% of its revenue. It also owns Asteria Health, one of the facilities that compound hormones for its practitioners.
Its biggest risks, as it describes them
- The Biote Method and its supplements may not win enough acceptance among clinics, practitioners and patients.
- Its reliance on a few compounding pharmacies and contract makers, whose failures could hurt patients and its reputation.
- Regulators could tighten rules on compounded bioidentical hormones, which would sharply affect its revenue.
- Its practitioners and clinics are concentrated in a few regions of the country.
- Weaknesses in its financial reporting controls, which led it to restate earlier financial statements.
Income statement
From fiscal 2023 to 2025, earnings per share grew 138.6% a year and net income 186.0% a year, as new shares raised the share count by 43% and diluted each share's earnings.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 0 | 79 | 89 | 39 | 24 |
| Debt incl. finance leases | 37 | 122 | 116 | 109 | 103 |
| Net debt (negative means net cash) | 37 | 43 | 27 | 70 | 79 |
| Net debt to EBITDA | 1.0x | — | 0.8x | 2.0x | 2.0x |
| Debt to equity | 9.0x | — | — | — | — |
| Interest coverage | 23.6x | −13.7x | 3.0x | 3.3x | 4.5x |
| Current ratio | 2.7x | 5.4x | 5.5x | 1.3x | 1.2x |
| Quick ratio | 2.2x | 4.8x | 4.7x | 1.0x | 0.8x |
Cash flow
Projections
Project biote's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What biote says to expect
- Full year 2026: dietary supplements revenue
We continue to expect full-year 2026 dietary supplements revenue to grow at a mid- to high-single-digit rate from 2025.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 1 insider bought $202,204 of biote shares on the open market, and none sold any.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 11, 2026 | Marc D BeerExecutive Chairman, Director | Bought | 16,000 | $1.55 | $24,800 | Form 4 |
| Aug 10, 2026 | Marc D BeerExecutive Chairman, Director | Bought | 115,950 | $1.53 | $177,404 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 6 of 8 | 4 of 8 | 5 of 8 |
| Rule of 40 | 26.7% | 26.1% | 13.2% |
| Altman Z'' | 4.65 | −0.52 | 0.97 |
| Accruals ratio | −17.7% | −30.3% | −7.1% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Pass | Pass | Pass |
| Cash from operations is positive | Pass | Pass | Pass |
| Return on assets rose | Pass | Fail | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Pass | Pass | Fail |
| Current ratio rose | Pass | Fail | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Fail | Fail | Pass |
| F-score | 6 of 8 | 4 of 8 | 5 of 8 |
Compare
Put biote side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| biote | FY25 | −2.5% | 18.5% | 15.7% | — | 2.0x | 5 | |
| LifeMD | FY25 | 25.3% | −4.0% | 3.3% | — | — | — | Compare |
| Strata Critical Medical | FY25 | 34.3% | −11.3% | −29.7% | −11.3% | — | 4 | Compare |
| SBC Medical Group | FY25 | −15.5% | 38.9% | 13.4% | 38.4% | −1.7x | 4 | Compare |
| AirSculpt Technologies | FY25 | −15.8% | −7.6% | 0.5% | −6.6% | 39.0x | 3 | Compare |
5 years of figures
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | 139 | 165 | 185 | 197 | 192 |
| Revenue growth | — | 18.3% | 12.4% | 6.4% | −2.5% |
| Gross profit | — | — | — | — | — |
| Research and development | — | — | — | — | — |
| Operating income | 35 | −61 | 29 | 32 | 36 |
| Net income | 11 | −1 | 3 | 3 | 27 |
| Diluted EPS (US$) | — | −0.12 | 0.13 | 0.09 | 0.74 |
| Diluted shares (millions) | — | 8 | 26 | 34 | 37 |
| Cash flow | |||||
| Cash from operations | 34 | −9 | 27 | 45 | 35 |
| Capital expenditure | 1 | 0 | 0 | 6 | 5 |
| Free cash flow | 32 | −9 | 27 | 39 | 30 |
| Dividends paid | 11 | 13 | 9 | 5 | 2 |
| Share buybacks | 0 | 0 | 0 | 6 | 3 |
| Acquisitions | 0 | 0 | 0 | 12 | 0 |
| Stock-based compensation | — | 82 | 9 | 9 | 9 |
| Balance sheet at fiscal year end | |||||
| Cash and short-term investments | 0 | 79 | 89 | 39 | 24 |
| Debt incl. finance leases | 37 | 122 | 116 | 109 | 103 |
| Total assets | 54 | 112 | 155 | 122 | 108 |
| Total liabilities | 50 | 170 | 192 | 225 | 158 |
| Shareholders' equity | 4 | −44 | −29 | −106 | −58 |
| Margins and ratios | |||||
| Gross margin | — | — | — | — | — |
| Operating margin | 24.8% | −36.8% | 15.5% | 16.0% | 18.5% |
| Net margin | 8.0% | −0.6% | 1.8% | 1.6% | 14.1% |
| Free cash flow margin | 23.1% | −5.8% | 14.3% | 19.7% | 15.7% |
| Rule of 40 (growth + FCF margin) | — | 12.6% | 26.7% | 26.1% | 13.2% |
| Return on capital | — | −370.8% | — | — | — |
| Return on equity | — | — | — | — | — |
| Return on assets | — | −1.2% | 2.5% | 2.3% | 23.5% |
| Net debt to EBITDA | 1.0x | — | 0.8x | 2.0x | 2.0x |